AVEO is a late-stage biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. Their proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. AVEO’s leadership position in cancer therapeutics has been demonstrated through its advancing clinical and discovery pipeline and its ability to secure industry partnerships with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough and Biogen Idec.

Flagship Ventures General Partner Doug Cole is on the Board of Directors.

www.aveopharma.com